Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2

Liu, An; Sun, Kuo; Wang, Junjie; Wang, Shuocun; Zhao, Xin; Liu, Runhui; Lu, Yiming

doi:10.1016/j.pep.2021.105857

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant expression of TNFR2 on tumor cells has been shown in many recent studies with evidence of the key role of this receptor in tumor progression in rodents and humans (27). TNFR2 is aberrantly expressed on various cancer cells and highly immunosuppressive Tregs accumulated in the tumor microenvironment.…”

Section: Cytokine Profilesmentioning

confidence: 97%

“…There are two receptors of TNF-α: tumor necrosis factor 1 receptor (TNFR1), present on almost all cell types, while tumor necrosis factor 2 receptor (TNFR2) expression is restricted to minor subpopulations of the lymphoid system including regulatory T cells (Tregs) and myeloid suppressor cells, endothelial cells, and certain tumor cells (23,27).…”

Section: Cytokine Profilesmentioning

confidence: 99%

See 1 more Smart Citation

Modern markers for evaluating bone disease in multiple myeloma (Review)

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a bone marrow neoplasia with increasing incidence compared to previous years. Although new therapeutic molecules have been introduced, it remains an incurable disease with severe repercussions to patients. For many patients, bone disease represents a severe problem often causing pain, pathological bone fractures, and spinal cord compression, which affects the quality of life. This article analyzes the main markers of bone destruction in MM as well as risk factors for severe bone damage. Bone complications have a negative impact on the quality of life of patients with MM, along with other associated complications (renal failure, hypogammaglobulinemia, osteolytic bone disease, hypercalcemia, anemia). The markers of bone destruction described in this article include: interleukin (IL)-6, tumor necrosis factor (TNF)-α, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG), amino-and carboxy-terminal cross-linking telopeptide of type I collagen (NTX, CTX), human bone sialoprotein (BSP) and dickkopf-1 secreted glycoprotein (DKK1). The future practical applicability of this literature review would be the large-scale determination of markers of bone destruction that correlate with the negative evolution to complications of bone disease or the implications that these markers have in regards to treatment.

show abstract

Section: Cytokine Profilesmentioning

confidence: 97%

Section: Cytokine Profilesmentioning

confidence: 99%

Modern markers for evaluating bone disease in multiple myeloma (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

The implications of the TNFα‐TNFR2 immune checkpoint signaling pathway in cancer treatment: From immunoregulation to angiogenesis

Emamalipour,

Shamdani,

Mansoori

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Despite the tremendous advances that have been made in biomedical research, cancer remains one of the leading causes of death worldwide. Several therapeutic approaches have been suggested and applied to treat cancer with impressive results. Immunotherapy based on targeting immune checkpoint signaling pathways proved to be one of the most efficient. In this review article, we will focus on the recently discovered TNFα‐TNFR2 signaling pathway, which controls the immunological and pro‐angiogenic properties of many immunoregulatory and pro‐angiogenic cells such as endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), and regulatory T cells (Tregs). Due to their biological properties, these cells can play a major role in cancer progression and metastasis. Therefore, we will discuss the advantages and disadvantages of an anti‐TNFR2 treatment that could carry two faces under one hood. It interrupts the immunosuppressive and pro‐angiogenic behaviors of the above‐mentioned cells and interferes with tumor growth and survival.

show abstract

Design of minibinder proteins specific to TNFR1

Weng,

Miaomiao,

et al. 2024

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2

Cited by 5 publications

References 24 publications

Modern markers for evaluating bone disease in multiple myeloma (Review)

Modern markers for evaluating bone disease in multiple myeloma (Review)

The implications of the TNFα‐TNFR2 immune checkpoint signaling pathway in cancer treatment: From immunoregulation to angiogenesis

Design of minibinder proteins specific to TNFR1

Contact Info

Product

Resources

About